Best Supplements for Reduced Interleukin-6 Levels
Ranked by research evidence. Compare 85 supplements across 124 papers from the biomedical literature, with effect direction, evidence strength, and dose range for each.
Top picks by evidence
- Moderate evidence8 studies
Across 8 studies, 5 reported beneficial effects (4 statistically significant) and 3 reported neutral effects, with no harmful findings. The predominant effect size is small to moderate, with the most robust evidence coming from RCTs showing moderate effects in clinical populations (e.g., colorectal cancer patients, overweight/obese adults). Doses ranged from 200 IU/day to personalized loading doses, and the median study duration was 56 days, indicating effects typically observed at 8–12 weeks.
Dose: 200–5000 IU/day (most consistent evidence near 2000 IU/day or personalized loading doses)Product matchViva Naturals — Vitamin D3 with Organic Liquid Coconut Oil125 mcg · $15.16 · ★5.0 (208) - Moderate evidence6 studies
Across 6 papers, 4 report beneficial effects of vitamin C on reducing IL-6 levels, with effect sizes ranging from small to moderate; 2 studies show neutral results. The most-studied dose is 1000 mg/day, and studies primarily involve clinical populations (e.g., cardiac surgery, septic shock, sarcopenia). Effects are observed at durations from acute single doses up to 12 weeks, with a median study duration of 28 days.
Dose: 1000 mg daily - Moderate evidence3 studies
All 3 studies found moderate beneficial effects of black cumin (Nigella sativa) supplementation on reducing interleukin-6 levels, with statistically significant results in each. Doses ranged from 200 to 4600 mg/day, but the most commonly studied dose was 2000 mg/day. Effects were observed in general and clinical populations, with study durations ranging from 1 to 8 weeks.
- ModerateVitamin DAcross 8 studies, 5 reported beneficial effects (4 statistically significant) and 3 reported neutral effects, with no harmful findings. The predominant effect size is small to moderate, with the most robust evidence coming from RCTs showing moderate effects in clinical populations (e.g., colorectal cancer patients, overweight/obese adults). Doses ranged from 200 IU/day to personalized loading doses, and the median study duration was 56 days, indicating effects typically observed at 8–12 weeks. · Dose: 200–5000 IU/day (most consistent evidence near 2000 IU/day or personalized loading doses)5 beneficial3 neutral8 studies
- ModerateVitamin CAcross 6 papers, 4 report beneficial effects of vitamin C on reducing IL-6 levels, with effect sizes ranging from small to moderate; 2 studies show neutral results. The most-studied dose is 1000 mg/day, and studies primarily involve clinical populations (e.g., cardiac surgery, septic shock, sarcopenia). Effects are observed at durations from acute single doses up to 12 weeks, with a median study duration of 28 days. · Dose: 1000 mg daily4 beneficial2 neutral6 studies
- ModerateBlack CuminAll 3 studies found moderate beneficial effects of black cumin (Nigella sativa) supplementation on reducing interleukin-6 levels, with statistically significant results in each. Doses ranged from 200 to 4600 mg/day, but the most commonly studied dose was 2000 mg/day. Effects were observed in general and clinical populations, with study durations ranging from 1 to 8 weeks.3 beneficial3 studies
- LowTurmericAcross 4 studies, 2 reported beneficial moderate-sized effects on reducing interleukin-6 (IL-6) levels, while 2 found neutral results with small or no effect. The predominant effect direction is beneficial, but effect sizes were mixed (moderate for beneficial studies vs. small for neutral studies). The most studied population was clinical (e.g., chronic lower back pain, knee osteoarthritis, metabolic syndrome), with a median study duration of 84 days, suggesting effects are typically observed at 8-12 weeks.2 beneficial2 neutral4 studies
- LowPropolisAcross 4 studies, 2 reported beneficial effects on interleukin-6 levels, while 2 found no significant effect; the predominant effect size was mixed (small to large). The evidence base includes meta-analyses in clinical populations with type 2 diabetes, but no consistent dose range or duration was reported. Overall, propolis shows mixed evidence for reducing IL-6, with findings varying by study design and population.2 beneficial2 neutral4 studies
- LowWhey ProteinAcross 3 studies, 1 reported a beneficial small-sized effect on reducing interleukin-6 levels, while 2 found neutral effects (no significant reduction). The sole beneficial study was a large meta-analysis in older adults with sarcopenia (n=1154), which reported a significant small effect. The median study duration was 56 days (based on 1 study), though limited duration data prevents strong conclusions about timing. The most studied population was clinical (sarcopenia, frailty, hemodialysis patients).1 beneficial2 neutral3 studies